Requirement of cannabinoid CB(1) receptors in cortical pyramidal neurons for appropriate development of corticothalamic and thalamocortical projections.
A role for endocannabinoid signaling in neuronal morphogenesis as the brain develops has recently been suggested. Here we used the developing somatosensory circuit as a model system to examine the role of endocannabinoid signaling in neural circuit formation. We first show that a deficiency in cannabinoid receptor type 1 (CB(1)R), but not G-protein-coupled receptor 55 (GPR55), leads to aberrant fasciculation and pathfinding in both corticothalamic and thalamocortical axons despite normal target recognition. Next, we localized CB(1)R expression to developing corticothalamic projections and found little if any expression in thalamocortical axons, using a newly established reporter mouse expressing GFP in thalamocortical projections. A similar thalamocortical projection phenotype was observed following removal of CB(1)R from cortical principal neurons, clearly demonstrating that CB(1)R in corticothalamic axons was required to instruct their complimentary connections, thalamocortical axons. When reciprocal thalamic and cortical connections meet, CB(1)R-containing corticothalamic axons are intimately associated with elongating thalamocortical projections containing DGLβ, a 2-arachidonoyl glycerol (2-AG) synthesizing enzyme. Thus, 2-AG produced in thalamocortical axons and acting at CB(1)Rs on corticothalamic axons is likely to modulate axonal patterning. The presence of monoglyceride lipase, a 2-AG degrading enzyme, in both thalamocortical and corticothalamic tracts probably serves to restrict 2-AG availability. In summary, our study provides strong evidence that endocannabinoids are a modulator for the proposed 'handshake' interactions between corticothalamic and thalamocortical axons, especially for fasciculation. These findings are important in understanding the long-term consequences of alterations in CB(1)R activity during development, a potential etiology for the mental health disorders linked to prenatal cannabis use.
Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
Chia-Shan
CS
Wu
Jie
J
Zhu
Jim
J
Wager-Miller
Shan
S
Wang
Dennis
D
O'Leary
Krisztina
K
Monory
Beat
B
Lutz
Ken
K
Mackie
Hui-Chen
HC
Lu
D000818:Animals; D000831:Animals, Newborn; D063385:Cannabinoid Receptor Modulators / Q000378:metabolism / Q000502:physiology; D002540:Cerebral Cortex / Q000196:embryology* / Q000254:growth & development*; D005260:Female; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009024:Morphogenesis / Q000235:genetics / Q000502:physiology*; D009434:Neural Pathways / Q000196:embryology / Q000254:growth & development*; D056347:Neuroanatomical Tract-Tracing Techniques / Q000379:methods; D017966:Pyramidal Cells / Q000196:embryology / Q000254:growth & development*; D043884:Receptor, Cannabinoid, CB1 / Q000235:genetics / Q000502:physiology*; D043882:Receptors, Cannabinoid / Q000235:genetics / Q000502:physiology; D013788:Thalamus / Q000196:embryology / Q000254:growth & development*
D063385:Cannabinoid Receptor Modulators; C526692:GPR55 protein, mouse; D043884:Receptor, Cannabinoid, CB1; D043882:Receptors, Cannabinoid